Home > Investor Relations
Achillion is focused on solutions for the most challenging problems in infectious disease.
The investor pages that follow are your resource for financial information about Achillion Pharmaceuticals. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.
Mar 14, 2014
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
Mar 7, 2014